Bramsia 150 mg tablete s produljenim oslobađanjem
| Name | Bramsia 150 mg tablete s produljenim oslobađanjem |
|---|---|
| Marketing Authorisation Number | HR-H-353070693 |
| Active Substance | tapentadolfosfat |
| Composition | jedna tableta s produljenim oslobađanjem sadrži tapentadolfosfat u količini koja odgovara 150 mg tapentadola |
| Pharmaceutical Form | Tableta s produljenim oslobađanjem |
| Manufacturer | Develco Pharma GmbH, Schopfheim, Njemačka |
| Marketing Authorisation Holder | Viatris Limited, Damastown Industrial Park, Mulhuddart, Dublin, Irska |
| Marketing Authorisation Date | 20.10.2022 |
| MA Period of Validity | 20.10.2027 |
| MA Revocation Date | 30.06.2023* |
| Classification Number | UP/I-530-09/22-01/16 |
| Registration Number | 381-12-01/38-22-05 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | poseban recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | N02AX06 |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
| Summary of risk management plan | download |
*Note
Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act (Official Gazette No. 76/13), only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.
